Table 1.
Basic demographic data of patients with BCLC stage B hepatocellular carcinoma of various treatments
| Variable | SR (n = 140) | TACE (n = 231) | TACE+RFA (n = 57) | Total (n = 428) | P-value |
|---|---|---|---|---|---|
| Male | 117 (83.6) | 173 (74.9) | 43 (75.4) | 333 (77.8) | 0.134 |
| Age (years) | 62 (35–82) | 64 (29–91) | 64 (28–86) | 63 (25–91) | 0.311 |
| Smoking | 68 (48.6) | 113 (48.9) | 27 (47.4) | 208 (48.6) | 0.978 |
| Alcohol use | 58 (41.4) | 100 (43.3) | 23 (40.4) | 181 (42.3) | 0.894 |
| HBV positive | 70 (50.0) | 103 (44.6) | 32 (56.1) | 205 (47.9) | 0.245 |
| HCV positive | 30 (21.4) | 90 (39.0) | 21 (36.8) | 141 (32.9) | 0.002 |
| Total Bilirubin | 1.03 ± 0.43 | 1.34 ± 1.14 | 1.40 ± 0.66 | 1.24 ± 0.91 | 0.003 |
| INR | 1.00 ± 0.06 | 1.06 ± 0.12 | 1.10 ± 0.14 | 1.05 ± 0.11 | < 0.0001 |
| Cirrhosis | 36 (25.7) | 155 (67.1) | 43 (75.4) | 234 (54.7) | < 0.0001 |
| Child-Pugh class A | 134 (95.7) | 194 (84.0) | 44 (77.2) | 372 (86.9) | < 0.0001 |
| Tumor size | 8.2 ± 3.3 | 7.0 ± 3.8 | 5.5 ± 2.6 | 7.0 ± 3.6 | 0.001 |
| Tumor size≥5 cm | 127 (90.7) | 149 (64.5) | 25 (43.8) | 289 (67.5) | < 0.0001 |
| Tumor number (≥3) | 49 (35.0) | 178 (77.1) | 51 (89.5) | 278 (65.0) | < 0.0001 |
| AFP (ng/mL) ≥ 200 | 34 (24.3) | 50 (21.6) | 7 (12.1) | 91(21.3) | 0.171 |
| Mortality | 50 (35.7) | 173 (74..9) | 34 (59.6) | 257 (60.0) | < 0.0001 |
| Follow-up times (months) | 39 (1–98) | 22 (1–97) | 37 (3–95) | 29 (1–98) | < 0.001 |
BCLC stage Barcelona clinic liver cancer; SR Surgical resection; TACE Transcatheter arterial chemoembolization; RFA Radiofrequency ablation; HBV Hepatitis B virus; HCV Hepatitis C virus; AFP: INR International normalize ratio; Alpha-fetoprotein;